We observed a high frequency of MGMT and CALCA methylation in NSGCTs and demonstrated for the first time that CALCA methylation is associated with non-seminoma tumors, refractory disease, and poor clinical outcome in TGCT patients (range, 26–32 years) [69]. Here, CALCA is linked to seminoma.